0000950157-15-000825.txt : 20150727 0000950157-15-000825.hdr.sgml : 20150727 20150727163847 ACCESSION NUMBER: 0000950157-15-000825 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150721 ITEM INFORMATION: Other Events FILED AS OF DATE: 20150727 DATE AS OF CHANGE: 20150727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36172 FILM NUMBER: 151007442 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 form8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):   July 21, 2015

ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)


Delaware
001-36172
22-3106987
(State or other jurisdiction of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)


 
26 Landsdowne Street, Cambridge, Massachusetts
  
02139
  
 
(Address of principal executive offices)
  
(Zip Code)
  


Registrant's telephone number, including area code: (617) 494-0400

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 8.01                      Other Events.
 
Effective July 21, 2015, ARIAD Pharmaceuticals, Inc. (the “Company”) granted an exemption to (1) Putnam Investments, LLC d/b/a/ Putnam Investments (“Putnam”), (2) Putnam Investment Management, LLC, The Putnam Advisory Company, LLC, Putnam Fiduciary Trust Company and any other direct or indirect subsidiary of Putnam which acts, or may in the future act, as an investment advisor or fund manager (the “Putnam Advisors”), (3) any direct or indirect subsidiary of Putnam or any fund, managed account or other investment entity for which a Putnam Advisor serves as investment advisor or fund manager and (4) any Affiliate or Associate (each as defined in the Rights Agreement (as defined below)) of the foregoing (collectively, the “Putnam Parties”) under the Company’s Section 382 Rights Agreement, between the Company and Computershare Trust Company, N.A., as rights agent (the “Rights Agreement”), dated as of October 31, 2013 and as amended on June 24, 2014.  The grant of the exemption followed the determination by a designated committee of the Board of Directors (the “Board”) of the Company that the Putnam Parties are not collectively an “Acquiring Person” pursuant to Section 29 of the Rights Agreement.

The Board adopted the Rights Agreement to protect stockholder value by deterring acquisitions of the Company’s common stock that would potentially limit the Company’s ability to use its net operating loss carryforwards (“NOLs”) and other tax benefits, which may be used to reduce potential future income tax obligations.  In general, the rights issued under the Rights Agreement impose a significant penalty on any person, together with its Affiliates, that acquires 4.99% or more of the common stock of the Company then outstanding, unless such person is determined to not be an “Acquiring Person” or is otherwise excluded from the Rights Agreement.

Putnam made representations and covenants sufficient to cause the designated committee of the Board to conclude that the exemption would not jeopardize the availability of the Company’s NOLs and other tax benefits.  The designated committee of the Board determined that the Putnam Parties will not be deemed to be an “Acquiring Person” so long as the Putnam Parties remain in compliance with those representations and covenants.
 
2
 
 
Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
ARIAD Pharmaceuticals, Inc.
  
       
 
By:
/s/ Thomas J. DesRosier  
    Name:  Thomas J. DesRosier  
    Title:    Chief Legal and Administrative Officer  
       
 
 
Date: July 27, 2015
 
 
 
3